2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

De Ramón, C, Rojas, EA, Misiewicz-Krzeminska, I, Cardona-Benavides, IJ, Cuadrado, M, Isidro, I, Calasanz, MJ, Fernandez, M, García-Sanz, R, Puig, N, Cedena, MT, Paiva, B, Rosiñol, L, Martínez-López, J, Bladé, J, Lahuerta, JJ, San Miguel, JF, Mateos, MV, Corchete, LA, Gutiérrez, NC, GEM PETHEMA Cooperat Study Grp. Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients. HEMASPHERE 8 -. 1 dic 2024. . . F.I.:7,600 [doi:10.1002/hem3.70036]

González-Calle, V, Rodriguez-Otero, P, Calasanz, MJ, Guijarro, M, Martínez-López, J, Rosiñol, L, Hernández, MT, Teruel, AI, Gironella, M, Oriol, A, de la Rubia, J, González-Rodríguez, AP, Bargay, J, de Arriba, F, Palomera, L, González-Pérez, MS, Sureda, A, Ocio, E, Lahuerta, JJ, Bladé, J, San Miguel, JF, Mateos, MV, Gutiérrez, NC. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. HEMASPHERE 8 -. 1 dic 2024. . . F.I.:7,600 [doi:10.1002/hem3.70031]

Puig, N, Agullo, C, Contreras, T, Perez, JJ, Aires, I, Calasanz, MJ, Garcia-Sanz, R, Castro, S, Martinez-Lopez, J, Rodriguez-Otero, P, Gonzalez-Calle, V, Gonzalez, MS, Oriol, A, Gutierrez, NC, Rios-Tamayo, R, Rosinol, L, Alvarez, MA, Bargay, J, Gonzalez-Rodriguez, AP, Alegre, A, Escalante, F, Inigo, MB, de la Rubia, J, Teruel, AI, de Arriba, F, Palomera, L, Hernandez, MT, Lopez-Jimenez, J, Reinoso, M, Garcia-Mateo, A, Ocio, EM, Blade, J, Lahuerta, JJ, Cedena, MT, Paiva, B, Miguel, JFS, Mateos, MV. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome inpatients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial. HAEMATOLOGICA 109 4056-4066. 1 dic 2024. . . F.I.:8,200 [doi:10.3324/haematol.2024.285742]

Gil-Etayo, FJ, Niño-Ramírez, JE, Fonseca-Santos, M, Arroyo-Sánchez, D, Navarro-Bailón, A, Parra, AV, Hernaz, IJ, Sánchez, PT, Boix, F, Alcoceba, M, Marin, L, Pérez-López, E, Cabrero, M, Martín-López, AA, López, M, Baile, M, Avendaño, A, Cabero, A, García-Bacelar, A, Vázquez, L, Sánchez-Guijo, F, García-Sanz, R, López-Corral, L, Velarde, AT. Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy. HLA 104 -. 1 nov 2024. . . F.I.:5,900 [doi:10.1111/tan.15738]
Moreno, DF, Jiménez, C, Escalante, F, Askari, E, Castellanos-Alonso, M, Arnao, M, Heredia, A, Canales, MA, Alcalá, M, Bermúdez, A, Carreres, AS, Casanova, M, Palomera, L, Motlló, C, García-Sánchez, R, Rull, PR, García-Sanz, R, de Larrea, CF. Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry. HEMASPHERE 8 -. 1 nov 2024. . . F.I.:7,600 [doi:10.1002/hem3.70029]

Gil-Etayo, FJ, Arroyo-Sánchez, D, Ramírez, JEN, Terradillos-Sánchez, P, Velarde, AT. Detection of the novel HLA-DQA1*05:73 allele with an amino acid substitution in the a2 extracellular domain. HLA 104 -. 1 oct 2024. . . F.I.:5,900 [doi:10.1111/tan.15707]
Fernández-Sánchez, A, Hernández-Sánchez, A, De Ramón, C, Chillón, MC, Vidriales, MB, Baile-González, M, Fuentes-Morales, CT, Sierra-Pacho, M, López-Corral, L, Sánchez-Guijo, F. Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/RUNX1::RUNX1T1: Selecting Optimal Treatment Based on Clinical and Molecular Findings. BIOMEDICINES 12 -. 1 oct 2024. . . F.I.:3,900 [doi:10.3390/biomedicines12102339]

Martinez-Verbo, L, Veselinova, Y, Llinàs-Arias, P, García-Prieto, CA, Noguera-Castells, A, Pato, ML, Bueno-Costa, A, Campillo-Marcos, I, Villanueva, L, Oliver-Caldes, A, Cardus, O, Salsench, SV, García-Ortiz, A, Valeri, A, Rojas, EA, Barrena, N, Gutiérrez, NC, Prósper, F, Agirre, X, de Larrea, CF, Martínez-López, J, Ferrer, G, Esteller, M. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma. LEUKEMIA 38 2722-2726. 24 sep 2024. 1 sep 2024. . F.I.:12,800 [doi:10.1038/s41375-024-02419-z]

Mateos, MV, Martínez-López, J, Otero, PR, González-Calle, V, Gonzalez, MS, Oriol, A, Gutiérrez, NC, Rios-Tamayo, R, Rosiñol, L, Rivas, MAA, Bargay, J, Gonzalez-Rodriguez, AP, Alegre, A, Escalante, F, Rodriguez, MBI, de la Rubia, J, Teruel, AI, de Arriba, F, Palomera, L, Hernández, MT, Jiménez, JL, Reinoso-Segura, M, Mateo, AG, Ocio, EM, Paiva, B, Puig, N, Cedena, MT, Blade, J, Lahuerta, JJ, San-Miguel, JF. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J CLIN ONCOL 42 -. 20 sep 2024. . . F.I.:42,100 [doi:10.1200/JCO.23.02771]

Tedeschi, A, Tam, CS, Owen, RG, Buske, C, Leblond, V, Dimopoulos, M, Garcia-Sanz, R, Castillo, JJ, Trotman, J, Treon, SP, Yang, KR, Tang, BX, Allewelt, H, Patel, S, Chan, WY, Cohen, A, Chen, SN, Barnes, G. Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial. FUTURE ONCOL 20 1789-1798. 8 ago 2024. 1 jul 2024. . F.I.:3,000 [doi:10.1080/14796694.2024.2355079]